Search Results
Your search for The ASCO ,The ASCO matches 21475 pages
Showing 20801 - 20850Mammography Has Led to Fewer Late-Stage Breast Cancers, Study Finds
In the past 30 years, since mammography was introduced, late-stage breast cancer incidence has decreased by 37%, a new study published in Cancer has found. The analysis by Helvie et al took into account an observed underlying trend of increased breast cancer incidence present since the 1940s....
ASCO 2014: Stopping Statins Is Safe and Can Improve Quality of Life for Patients With Cancer Near the End of Life
Stopping statin therapy is safe for patients with cancer who have a life expectancy of less than 1 year, according to a randomized study reported at the 2014 ASCO Annual Meeting in Chicago (Abstract LBA9514). Discontinuing statins did not shorten survival and provided a number of important...
ASCO 2014: Goserelin Helps Preserve Fertility Among Women Receiving Chemotherapy for Hormone Receptor–Negative Breast Cancer
Adding goserelin (Zoladex) to standard chemotherapy may be an effective method of preserving fertility among women with early-stage hormone receptor–negative breast cancer, according to findings from a federally funded phase III clinical trial. In the S0230/POEMS study, reported at the 2014...
ASCO 2014: Starting Palliative Care Support for Family Caregivers at the Time of Cancer Diagnosis Improves Quality of Life
Introducing a palliative care support program for caregivers of patients with advanced cancer at or near the time patients are diagnosed provides greater benefits than delayed palliative care services, according to results of the ENABLE III study reported at the 2014 ASCO Annual Meeting in Chicago...
ASCO 2014: Enzalutamide Before Chemotherapy Prolongs Progression-Free and Overall Survival in Metastatic Prostate Cancer
The androgen receptor inhibitor enzalutamide (Xtandi) has been shown to prolong survival in men with metastatic castration-resistant prostate cancer with progressive disease after chemotherapy. In the phase III PREVAIL trial reported in The New England Journal of Medicine, Beer et al found that...
ASCO 2014: Women With Breast Cancer and Bone Metastasis Can Safely Scale Back Frequency of Zoledronic Acid Dosing
Findings from a phase III randomized study suggest that women with breast cancer and bone metastasis who have received at least nine doses of zoledronic acid over the previous year can safely scale back dosing from every 4 weeks to every 12 weeks without compromising the effectiveness of the...
ASCO 2014: Lower-Dose Radiation May Reduce Long-Term Side Effects Without Compromising Survival in Certain HPV-Positive Head and Neck Cancers
According to a phase II study, customizing radiation doses based on response to induction chemotherapy and other prognostic factors may allow lower doses of radiation therapy to be administered to some patients with human papillomavirus (HPV)-positive oropharyngeal cancer without compromising...
ASCO 2014: Ipilimumab/Nivolumab Combination Achieves Long-Term Survival for Patients With Advanced Melanoma
Concurrent treatment with ipilimumab (Yervoy) and nivolumab resulted in a 2-year survival rate of 79% for patients with advanced melanoma. “While this is a small trial, that is very impressive 2-year survival data,” noted Mario Sznol, MD, at a press briefing on progress in immunotherapy ...
ASCO 2014: PD-1–Targeting Antibody Pembrolizumab Produces Long-Term Responses in Patients With Metastatic Melanoma
Findings from a large phase I study of 411 patients with advanced melanoma show that the PD-1–targeting antibody pembrolizumab (MK-3475) produced responses in 34% of patients, including 28% of patients whose disease progressed on prior treatment with ipilimumab (Yervoy). Among those who...
ASCO 2014: Adjuvant Ipilimumab Significantly Improves Recurrence-Free Survival in Patients With High-Risk Stage III Melanoma
Adjuvant therapy with ipilimumab (Yervoy) for patients with high-risk stage III melanoma significantly improved recurrence-free survival, the primary endpoint of the phase III EORTC 18071/CA 184-029 study. Patients randomly assigned to receive ipilimumab had a 9-month absolute improvement in...
Smokers With BRCA2 Mutation Have Increased Risk of Developing Lung Cancer
Around a quarter of smokers who carry a mutation in the BRCA2 gene will develop lung cancer at some point in their lifetime, a large-scale, international study reveals. Scientists described a previously unknown link between lung cancer and a particular BRCA2 mutation, which occurs in around 2% of...
ASCO 2014: Cediranib Plus Olaparib Significantly Increases Progression-Free Survival in Women With Recurrent Ovarian Cancer
The combination of two investigational oral drugs, the PARP inhibitor olaparib and the antiangiogenic drug cediranib, significantly extended progression-free survival and increased the overall response rate compared to olaparib alone in a phase II study among women with recurrent,...
ASCO 2014: Lenvatinib Yields High Response Rates, Delays Progression in Patients With Radioiodine-Resistant Differentiated Thyroid Cancer
A phase III, multicenter, double-blind, placebo-controlled study found that the oral targeted drug lenvatinib is highly effective among patients with differentiated thyroid cancer resistant to standard radioiodine therapy. “The main result is an extraordinary improvement in progression-free...
ASCO 2014: Ceritinib Shows Rapid, Durable Response in ALK-Positive NSCLC
In a phase I study, ceritinib (Zykadia) was found to shrink tumors in patients with anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC), regardless of whether patients had received previous treatment with an ALK inhibitor. The study was presented at the 2014 ASCO...
ASCO 2014: Adding Lapatinib to Adjuvant Trastuzumab Does Not Improve Outcomes in Early-Stage HER2-Positive Breast Cancer
A large phase III study, ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation), found no statistically significant differences in 4-year disease-free survival among women with early HER2-positive breast cancer who received adjuvant treatment that combined the HER2-targeted drugs...
ASCO 2014: Chemotherapy Plus Either Bevacizumab or Cetuximab Results in Similar Survival Benefits in Metastatic Colorectal Cancer
Bevacizumab (Avastin) plus chemotherapy and cetuximab (Erbitux) plus chemotherapy produced equal survival benefits for patients with metastatic colorectal cancer and no KRAS mutations, according to results from a large federally funded phase III study presented at the 2014 ASCO Annual Meeting...
ASCO 2014: Adding Docetaxel to Androgen-Deprivation Therapy Significantly Improves Survival in Hormone-Sensitive Prostate Cancer
The addition of docetaxel to androgen-deprivation therapy extended survival for men with newly diagnosed hormone-sensitive prostate cancer by more than 13 months in the National Cancer Institute–led phase III E3805 study. The survival benefit was even greater for men with high-volume disease. ...
ASCO 2014: Adjuvant Exemestane With Ovarian Function Suppression Better at Preventing Breast Cancer Recurrence Than Tamoxifen
A joint analysis of two phase III trials demonstrated that the aromatase inhibitor exemestane more effectively prevents breast cancer recurrences than tamoxifen when either was given with ovarian function suppression to premenopausal women with hormone-sensitive cancers. Exemestane plus ovarian...
ASCO 2014: Addition of Chemotherapy to Radiotherapy Improves Survival in Low-Grade Glioma
In a long-term follow-up analysis of RTOG 9802, the addition of PCV (procarbazine [Matulane], lomustine [CeeNu], and vincristine) to radiotherapy prolonged both progression-free survival and overall survival in adult patients with low-grade glioma. The findings were reported at the 2014 ASCO Annual ...
ASCO 2014: Ibrutinib Significantly Delays Disease Progression and Extends Survival in Relapsed CLL
Early findings from the phase III RESONATE study indicate that ibrutinib (Imbruvica) produces durable tumor responses and marked improvement in survival over standard ofatumumab (Arzerra) for patients with relapsed chronic lymphocytic leukemia (CLL). “With ibrutinib, about 80% of patients...
ASCO 2014: Second-Line Treatment With Ramucirumab Plus Standard Docetaxel Extends Overall Survival in Advanced Lung Cancer
Patients with stage IV non–small cell lung cancer (NSCLC) who relapsed after initial platinum-based therapy experienced extended overall survival with a combination of the antiangiogenic agent ramucirumab (Cyramza) and standard chemotherapy with docetaxel, compared to patients receiving...
ASCO 2014: Investigational Anti–PD-L1 Antibody Demonstrates Promising Activity in Certain Patients With Metastatic Bladder Cancer
In a phase I study, the investigational anti–programmed death-ligand 1 (PD-L1) monoclonal antibody MPDL3280A demonstrated promising overall response rates in patients with previously treated metastatic urothelial bladder cancer whose tumors were characterized as PD-L1–positive. The ...
ASCO 2014: Bortezomib Combination Significantly Improves Progression-Free Survival in Newly Diagnosed Mantle Cell Lymphoma
An international, randomized phase III study found that replacing vincristine with bortezomib (Velcade) in R-CHOP (rituximab [Rituxan] plus cyclophosphamide, doxorubicin, vincristine, and prednisone) significantly improved outcomes in newly diagnosed patients with mantle cell lymphoma who were...
ASCO 2014: Patients With Metastatic Colon Cancer Respond to New Combination Therapy, Phase IB Study Shows
In a new study presented at the 2014 ASCO Annual Meeting in Chicago (Abstract 3516), researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vemurafenib (Zelboraf), cetuximab (Erbitux),...
ASCO 2014: Women With BRCA Mutations Report Significant Side Effects Following Risk-Reducing Salpingo-Oophorectomy
The majority of women with BRCA1 and BRCA2 mutations experience sexual dysfunction, menopausal symptoms, cognitive and stress issues, and poor sleep following risk-reducing salpingo-oophorectomy, according to results of a new study from the Abramson Cancer Center and the Perelman School of Medicine ...
ASCO 2014: Men Who Receive Radiation Therapy for Prostate Cancer Have Increased Long-Term Risk of Bladder or Rectal Cancer
Men with prostate cancer generally have an excellent prognosis, but questions remain about the risk of second primary malignancies after initial therapy for localized disease. According to a new study presented at the 2014 ASCO Annual Meeting in Chicago (Abstract 5034), although the overall risk of ...
Study Identifies Risk of Chemotherapy-Related Hospitalization for Early-Stage Breast Cancer Patients
Oncologists now have a new understanding of the toxicity levels of specific chemotherapy regimens used for women with early-stage breast cancer, according to research from The University of Texas MD Anderson Cancer Center. The retrospective study, reported in the Journal of Clinical Oncology by...
FDA Approves Palonosetron Hydrochloride to Prevent Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients
The U.S. Food and Drug Administration (FDA) has approved palonosetron hydrochloride (Aloxi) injection for the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy, in children aged 1...
ASCO Guideline Update Recommends Tamoxifen for Up to 10 Years for Women With Nonmetastatic Hormone Receptor–Positive Breast Cancer
The American Society of Clinical Oncology (ASCO) has issued an update to its clinical practice guideline on the use of adjuvant endocrine therapy for women with stage I to III hormone receptor–positive breast cancer. The guideline was published in the Journal of Clinical Oncology. Duration...
Gene Mutation Found for Aggressive Form of Pancreatic Cancer
Researchers have identified a mutated gene common to adenosquamous carcinoma tumors, the first known unique molecular signature for this rare, but particularly virulent, form of pancreatic cancer. The findings by Liu et al are published in Nature Medicine. Pancreatic cancer is the fourth leading...
FDA Approves Panitumumab Plus FOLFOX for Wild-Type KRAS Metastatic Colorectal Cancer
The U.S. Food and Drug Administration (FDA) has approved panitumumab (Vectibix) for use in combination with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as first-line treatment in patients with wild-type KRAS (exon 2) metastatic colorectal cancer. This approval converts the accelerated...
Majority of Women Undergoing Contralateral Prophylactic Mastectomy Have No Major Risk Factors for Developing Cancer in Both Breasts
Patients deciding to undergo contralateral prophylactic mastectomy as part of initial treatment for breast cancer is a growing challenge in the management of the disease. Removing the unaffected breast has not been shown to increase survival, and the more aggressive procedure is associated with...
Supportive Tumor Tissue Surrounding Cancer Cells Hinders Pancreatic Cancer Progression, Preclinical Study Reports
Fibrous tissue long suspected of making pancreatic cancer worse actually supports an immune attack that slows tumor progression but cannot overcome it, scientists at The University of Texas MD Anderson Cancer Center reported in the journal Cancer Cell. “This supportive tissue that’s...
The Cancer Community Mourns the Passing of Selma Schimmel
The cancer community is mourning the death of Selma Schimmel who passed away on May 21, 2014, from malignant psoas syndrome, a complication of ovarian cancer. Ms. Schimmel died at Providence Tarzana Medical Center near her home in Los Angeles, California. She was 59. A tireless and fierce advocate ...
Study Uses Comprehensive Genomic Tumor Testing to Match Lung Cancer Patients With Targeted Therapies
In a recent study by the Lung Cancer Mutation Consortium (LCMC), investigators incorporated tumor genotyping into therapeutic decision-making for patients with lung adenocarcinomas. An oncogenic driver was detected in 64% of tumors from patients in this study. According to data from this study...
Study Reveals More Than One-Third of Patients With ‘Low-Risk’ Prostate Cancer on Conventional Biopsy Have More Aggressive Tumors on Targeted Biopsy
According to a new study by researchers at the University of California, Los Angeles, selection of men for active surveillance for prostate cancer should be based not on conventional biopsy, but on a new, imaging-guided targeted prostate biopsy. The new biopsy method is now a routine part of the...
Study Suggests Less Frequent Cardiac Screening May Be Preferable for Survivors of Childhood Cancer
One of the first studies to analyze the effectiveness of screening survivors of childhood cancer for early signs of impending congestive heart failure found improved health outcomes but suggested that less frequent screening than currently recommended may yield similar clinical benefit. Researchers ...
Studies Evaluate Racial Variations, Cost, and Influence of Access to Care in the Management and Treatment of Testicular Cancer
A series of studies evaluating the cost-effectiveness, risks, and outcomes associated with detecting, diagnosing, and treating testicular cancer were presented at a press conference during the 2014 Annual Scientific Meeting of the American Urological Association in Orlando, Florida. Although...
Results of Three Studies Indicate 17-Gene Assay Is a Significant Predictor of Prostate Cancer Aggressiveness at the Time of Diagnosis
According to the results from three studies published in European Urology, the 17-gene Oncotype DX Genomic Prostate Score is a significant predictor of disease aggressiveness at the time of diagnosis before intervention with radiation or surgery. The test provides more precise and individualized...
U.S. Cervical Cancer Rates Higher Than Previously Reported, Particularly Among Older Women and African American Women
Cervical cancer rates in the United States are higher than previously believed, particularly among 65- to 69-year-old women and African American women, according to a study by Rositch et al published in Cancer. Current U.S. cervical cancer screening guidelines do not recommend routine Pap smears...
Analysis Finds Wide Variation in Lung Cancer Rates Globally
The only recent comprehensive analysis of lung cancer rates for women around the world found that lung cancer rates are dropping in young women in many regions of the globe, pointing to the success of tobacco control efforts. However, rates continue to increase among older women in many countries,...
Necitumumab Plus Chemotherapy Shows Overall Survival Benefit in Patients With Squamous NSCLC
In the large phase III SQUIRE trial of necitumumab (IMC-11F8) in combination with gemcitabine and cisplatin in the first-line treatment of advanced squamous non–small cell lung cancer (NSCLC), patients with stage IV metastatic disease showed a statistically significant improvement in overall...
Obesity Substantially Increases Breast Cancer Mortality Only in Women With Premenopausal Estrogen Receptor–Positive Disease
A new study of 80,000 women with early breast cancer in 70 clinical trials finds that obesity is associated with a 34% higher risk of breast cancer–related death only among the 20,000 premenopausal women who had estrogen receptor–positive disease. Obesity had little effect in...
Study Projects Nationwide Low-Dose CT Screening Will Identify More—and Earlier-Stage—Lung Cancers, but Comes With Substantial Medicare Costs
A new model projects 5-year outcomes of implementing the recent U.S. Preventive Services Task Force (USPSTF) recommendations for annual low-dose computed tomography (CT) lung cancer screening in a high-risk Medicare population. The model estimates that gradual implementation of the screening...
Novel Targeted Drug May Provide a New Treatment Option for Patients With Recurrent Pigmented Villonodular Synovitis
According to early results from a phase I study, a new targeted drug, PLX3397, appears remarkably active against a rare neoplastic joint disorder known as pigmented villonodular synovitis. The study evaluated patients whose disease had progressed despite all other available therapies. More than...
New EGFR Inhibitor AZD9291 Shows Promising Activity in Treatment-Resistant Non–Small Cell Lung Cancer
Findings from a phase I study of a new mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, AZD9291, point to a promising new treatment option for patients with advanced, EGFR-mutant, non–small cell lung cancer (NSCLC) that is resistant to standard EGFR...
Delaying Androgen Deprivation Therapy May Be Safe for Men With Prostate Cancer Relapse Detected by PSA Testing
According to a large, population-based observational study of men who had a prostate-specific antigen (PSA)-only based relapse after prostate surgery or radiation therapy, delaying androgen deprivation therapy until the onset of symptoms or appearance of cancer on a scan does not substantially...
Novel Target Found for Chemotherapy-Resistant Leukemia Cells
Researchers at Children’s Hospital Los Angeles have discovered that by targeting a particular receptor, chemotherapy-resistant cancer cells can be killed in an acute form of childhood leukemia, offering the potential for a future treatment for patients who would otherwise experience relapse...
Immunotherapy May Be Effective in the Treatment of Multiple Myeloma
A new study by researchers at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James) provides evidence that genetically modifying immune cells might effectively treat multiple myeloma. The findings by ...
NIH Study Demonstrates That a New Cancer Immunotherapy Method Could Be Effective Against Epithelial Cell Cancers
A new method for using immunotherapy to specifically attack tumor cells that have mutations unique to a patient’s cancer has been developed by scientists at the National Cancer Institute (NCI), part of the National Institutes of Health. The researchers demonstrated that the human immune...
